Sirlander schreef op 26 november 2019 08:00:
VOLGENS MIJ HEBBEN ZE IETS TE VERTELLEN...
argenx Announces Upcoming Investor Events
Evercore ISI 2nd Annual HealthCONx Conference. Company presentation on Tuesday, December 3, 2019 at 8:00 a.m. ET in Boston.
Piper Jaffray 31st Annual Healthcare Conference. Company presentation on Wednesday, December 4, 2019 at 8:00 a.m. ET in New York.
Evening CIDP KOL Symposium. Company will host a key opinion leader (KOL) evening symposium focused on the potential of efgartigimod to treat patients with chronic inflammatory demyelinating polyneuropathy (CIDP) on Thursday, December 5, 2019 at 4:30 p.m. ET in New York. The event will feature:
Data from Phase 1 healthy volunteer trial of ENHANZE® subcutaneous (SC) formulation of efgartigimod and development path forward to evaluate SC formulation in efgartigimod indications, including in CIDP.
Additional presentations from argenx management on potential efgartigimod market opportunity in CIDP, biological rationale of evaluating efgartigimod in CIDP, and design of upcoming Phase 2 trial on track to start by end of year.
Guest speaker Richard Lewis, M.D. from Cedars-Sinai Medical Center, who will highlight the CIDP treatment landscape.